Veeva Systems Inc. $VEEV Shares Sold by Snider Financial Group

Posted by Stanley Muller on Oct 17th, 2026

Snider Financial Group lowered its position in Veeva Systems Inc. (NYSE:VEEV – Free Report) by 16.1% in the third quarter, Holdings Channel.com reports. The institutional investor owned 18,498 shares of the technology company’s stock after selling 3,538 shares during the period. Veeva Systems comprises approximately 1.3% of Snider Financial Group’s holdings, making the stock its 26th largest position. Snider Financial Group’s holdings in Veeva Systems were worth $5,280,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Aspiriant LLC purchased a new position in shares of Veeva Systems during the third quarter worth approximately $256,000. Perryman Financial Advisory Inc. AD increased its holdings in shares of Veeva Systems by 3.3% in the 3rd quarter. Perryman Financial Advisory Inc. AD now owns 12,280 shares of the technology company’s stock valued at $3,505,000 after acquiring an additional 394 shares during the period. Pension & Wealth Management Advisors Inc. purchased a new stake in Veeva Systems in the 3rd quarter valued at $38,000. Howard Capital Management LLC purchased a new stake in Veeva Systems in the 3rd quarter valued at $283,000. Finally, Formuepleje A S purchased a new stake in Veeva Systems in the 3rd quarter valued at $458,000. 88.20% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Veeva Systems news, Director Priscilla Hung sold 750 shares of the company’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $261.04, for a total transaction of $195,780.00. Following the completion of the transaction, the director owned 3,242 shares in the company, valued at approximately $846,291.68. This represents a 18.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jonathan Faddis sold 5,198 shares of the company’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $299.72, for a total transaction of $1,557,944.56. Following the transaction, the senior vice president owned 4,130 shares of the company’s stock, valued at approximately $1,237,843.60. The trade was a 55.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 56,789 shares of company stock valued at $14,913,889. 10.60% of the stock is owned by corporate insiders.

Key Headlines Impacting Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

Positive Sentiment: IQVIA selected Veeva’s clinical software as an enterprise standard. IQVIA will use Veeva Clinical Trial Management System, eTMF, Study Startup, and Site Connect across its global research operations. The agreement expands Veeva’s role in IQVIA’s clinical workflow, strengthens its position with contract research organizations and biopharma customers, and could support recurring revenue growth. Veeva Systems Becomes Default Clinical Software Across a Major Research Partner
Positive Sentiment: Technical momentum and institutional interest have accelerated. Reports said Veeva broke above a buy point as “big money” added exposure to the company’s AI-related software opportunity. Shares subsequently reached a fresh 52-week high and posted sizable single-session gains, attracting additional momentum-oriented investors. Veeva Stock Breaks Out As Big Money Grabs Exposure To The AI Software Play
Positive Sentiment: Analyst coverage remains favorable. Oppenheimer maintained a $325 price target, while the average Wall Street recommendation remains positive. These views reinforce the market’s expectation that Veeva can continue expanding despite a potential moderation in research-and-development growth. Oppenheimer Keeps $325 Target for Veeva Systems Stock
Neutral Sentiment: More than 175 emerging biotechs are reportedly using Veeva Basics, indicating continued adoption of the company’s broader cloud software platform. However, the immediate financial impact was not quantified. Veeva’s Clinical Technology Moat and IQVIA Deal
Negative Sentiment: Senior Vice President Jonathan Faddis sold 5,198 shares for approximately $1.56 million, reducing his direct ownership by 55.7%. The transaction occurred under a pre-arranged Rule 10b5-1 plan, which limits its significance as a discretionary bearish signal, but insider selling can still temper enthusiasm after a strong rally. SEC Insider Transaction Filing

Analyst Ratings Changes

VEEV has been the subject of a number of recent research reports. Guggenheim increased their price target on shares of Veeva Systems from $276.00 to $310.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Barclays lifted their price objective on shares of Veeva Systems from $275.00 to $315.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $295.00 target price on shares of Veeva Systems in a report on Thursday, August 27th. Wall Street Zen upgraded shares of Veeva Systems from a “hold” rating to a “buy” rating in a research note on Saturday, October 10th. Finally, Morgan Stanley increased their target price on shares of Veeva Systems from $215.00 to $275.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 27th. Nineteen analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $285.92.

Get Our Latest Stock Report on VEEV

Veeva Systems Price Performance

Shares of NYSE:VEEV traded down $2.13 during trading on Friday, reaching $310.90. The company had a trading volume of 1,730,063 shares, compared to its average volume of 1,686,745. The firm has a market capitalization of $50.34 billion, a price-to-earnings ratio of 51.14, a price-to-earnings-growth ratio of 1.34 and a beta of 0.93. The stock’s fifty day moving average price is $269.81 and its 200 day moving average price is $207.95. Veeva Systems Inc. has a fifty-two week low of $148.05 and a fifty-two week high of $319.95.

Veeva Systems (NYSE:VEEV – Get Free Report) last released its quarterly earnings results on Wednesday, August 26th. The technology company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.23 by $0.12. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%. The business had revenue of $927.96 million during the quarter, compared to analysts’ expectations of $905.38 million. During the same quarter in the prior year, the business earned $1.99 earnings per share. The company’s quarterly revenue was up 17.6% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, equities analysts anticipate that Veeva Systems Inc. will post 6.70 EPS for the current fiscal year.

About Veeva Systems

(Free Report)

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company’s product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.